electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore (Nasdaq: ECOR) announced that company management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (Nasdaq: ECOR) announced that company management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day. Investors seeking a meeting should contact their Canaccord Genuity sales representative or email electroCore Investor Relations at ecor@fnkir.com.
Details
News Market Reaction – ECOR
On Nov 11, the first trading day after this news, ECOR closed 1.29% above the previous close.
Data tracked by StockTitan Argus for the Nov 11 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day.
Investors who wish to request a meeting should contact their sales representative at Canaccord Genuity or reach out to electroCore Investor Relations at ecor@fnkir.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.